The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers

Basit Öğe Kaydı
dc.contributor.authorDemir M.E.
dc.contributor.authorÖzler T.E.
dc.contributor.authorMerhametsiz Ö.
dc.contributor.authorSözener U.
dc.contributor.authorUyar M.
dc.contributor.authorErcan Z.
dc.contributor.authorBardak Demir S.
dc.date.accessioned2024-03-13T10:01:08Z
dc.date.available2024-03-13T10:01:08Z
dc.date.issued2023
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractPurpose: Sodium-glucose co-transporter-2 inhibitor (SGLT-2i) administration is associated with some concerns in regard to the increased risk of genital and urinary tract infections (UTI) in kidney transplant recipients (KTR). In this study, we present the results of SGLT-2i use in KTR, including the early post-transplant period. Methods: Participants were divided into two groups: SGLT-2i-free diabetic KTR (Group 1, n = 21) and diabetic KTR using SGLT-2i (Group 2, n = 36). Group 2 was further divided into two subgroups according to the posttransplant prescription day of SGLT-2i; < 3 months (Group 2a) and ? 3 months (Group 2b). Groups were compared for development of genital and urinary tract infections, glycated hemoglobin a1c (HgbA1c), estimated glomerular filtration rate (eGFR), proteinuria, weight change, and acute rejection rate during 12-month follow-up. Results: Urinary tract infections prevalence was 21.1% and UTI-related hospitalization rate was 10.5% in our cohort. Prevalence of UTI and UTI-related hospitalization, eGFR, HgbA1c levels, and weight gain were similar between the SGLT-2i group and SGLT-2i-free group, at the 12-month follow-up. UTI prevalence was similar between groups 2a and 2b (p = 0.871). No case of genital infection was recorded. Significant proteinuria reduction was observed in Group 2 (p = 0.008). Acute rejection rate was higher in the SGLT-2i-free group (p = 0.040) and had an impact on 12-month follow-up eGFR (p = 0.003). Conclusion: SGLT-2i in KTR is not associated with an increased risk of genital infection and UTI in diabetic KTR, even in the early posttransplant period. The use of SGLT-2i reduces proteinuria in KTR and has no adverse effects on allograft function at the 12-month follow-up. © 2023, The Author(s), under exclusive licence to Springer Nature B.V.en_US
dc.description.sponsorshipSpecial thanks to Deren Gurbuz, MD, and Ceren Melissa Akkaya, MD.en_US
dc.identifier.doi10.1007/s11255-023-03645-7
dc.identifier.endpage2999en_US
dc.identifier.issn0301-1623
dc.identifier.issue11en_US
dc.identifier.pmid37289399en_US
dc.identifier.scopus2-s2.0-85161458438en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2989en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-023-03645-7
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3013
dc.identifier.volume55en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media B.V.en_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetesen_US
dc.subjectKidney transplantationen_US
dc.subjectNODATen_US
dc.subjectSGLT-2ien_US
dc.subjectUrinary tract infectionen_US
dc.titleThe results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu